Showing results (61-70 of 990) with videos related to
Sort By:
Pageof 99
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|October 4, 2005
Clinical trial designs for prospective validation of biomarkersSumithra J Mandrekar, Axel Grothey, Matthew P Goetz, et al.Molecular Genetics and Genomics : MGG|August 23, 2006
Analysis of S-RNase alleles of almond (Prunus dulcis): characterization of new sequences, resolution of synonyms and evidence of intragenic recombinationEncarnación Ortega, Radovan I Bosković, Daniel J Sargent, et al.JAMA Oncology|April 19, 2017
Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in OncologyVahid Montazerhodjat, Shomesh E Chaudhuri, Daniel J Sargent, et al.Computational and Mathematical Methods in Medicine|February 5, 2015
The direct assignment option as a modular design component: an example for the setting of two predefined subgroupsMing-Wen An, Xin Lu, Daniel J Sargent, et al.Nature Reviews. Clinical Oncology|September 4, 2013
Drug rechallenge and treatment beyond progression--implications for drug resistanceElizabeth A Kuczynski, Daniel J Sargent, Axel Grothey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)Harry H Yoon, David Tougeron, Qian Shi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.Biometrics|March 3, 2011
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trialsBrian P Hobbs, Bradley P Carlin, Sumithra J Mandrekar, et al.Nature Reviews. Clinical Oncology|April 7, 2010
Biomarkers and surrogate end points--the challenge of statistical validationMarc Buyse, Daniel J Sargent, Axel Grothey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Alternate endpoints for screening phase II studiesNeesha Dhani, Dongsheng Tu, Daniel J Sargent, et al.Pageof 99